Oxytocin Pilum: Uses, Dosage & Side Effects
Oxytocin 8.3 microgram/ml – Solution for injection/infusion
Oxytocin Pilum is a hospital-administered prescription medicine containing the synthetic hormone oxytocin. It is used to induce or strengthen labor contractions, manage miscarriage, control postpartum hemorrhage, and support uterine contraction during cesarean section. This guide covers uses, dosage, side effects, drug interactions, storage, and important safety information.
Quick Facts
Key Takeaways
- Oxytocin Pilum contains the synthetic hormone oxytocin and is used exclusively in hospital settings under medical supervision to induce labor, augment weak contractions, manage miscarriage, and control postpartum bleeding.
- It is administered as an intravenous infusion or intramuscular injection – never self-administered – and the dose is carefully titrated by healthcare professionals based on the patient's response.
- Common side effects include headache, nausea, vomiting, and changes in heart rate; rare but serious effects include uterine rupture, water intoxication, and anaphylaxis.
- Oxytocin must not be used within 6 hours of vaginal prostaglandin administration, and caution is required with QT-prolonging drugs and inhalational anesthetics.
- Store refrigerated at 2–8 °C; may be kept at room temperature (up to 25 °C) for a maximum of 3 months before use.
What Is Oxytocin Pilum and What Is It Used For?
Quick Answer: Oxytocin Pilum is a synthetic form of the naturally occurring hormone oxytocin. It stimulates contractions of the uterine smooth muscle and is used in obstetric practice to induce or augment labor, manage miscarriage or abortion, control postpartum hemorrhage, and support uterine contraction during cesarean section delivery.
Oxytocin is a peptide hormone produced naturally by the hypothalamus and released by the posterior pituitary gland. In its synthetic form, as contained in Oxytocin Pilum, it acts identically to the endogenous hormone by binding to specific oxytocin receptors on the myometrial (uterine muscle) cells. This binding triggers a cascade of intracellular events that increase calcium concentrations within the muscle cells, leading to rhythmic uterine contractions.
The sensitivity of the uterus to oxytocin increases progressively throughout pregnancy, reaching its peak near term. This physiological property makes synthetic oxytocin an invaluable tool in obstetric medicine. Oxytocin Pilum is manufactured by Pilum Pharma A/S (Denmark) and produced by JSC Grindeks in Riga, Latvia. Each 1 ml glass ampoule contains 8.3 micrograms of oxytocin, which is equivalent to approximately 5 International Units (IU).
Approved Indications
Oxytocin Pilum is approved for the following clinical uses:
- Induction of labor: When there is a medical need to initiate labor before it starts spontaneously, such as in post-term pregnancy, pre-eclampsia, or premature rupture of membranes.
- Augmentation of labor: When spontaneous labor has begun but contractions are inadequate (uterine inertia or dysfunctional labor), oxytocin can be used to strengthen and regulate the contraction pattern.
- Management of miscarriage and abortion: To facilitate uterine evacuation and reduce bleeding in cases of incomplete, inevitable, or missed miscarriage, as well as during therapeutic termination of pregnancy.
- Prevention and treatment of postpartum hemorrhage (PPH): Oxytocin is the first-line uterotonic agent recommended by the World Health Organization (WHO) for the prevention and management of PPH, which remains a leading cause of maternal mortality worldwide.
- Cesarean section: Administered after delivery of the baby to promote uterine contraction and reduce blood loss during and after surgical delivery.
According to the WHO Model List of Essential Medicines, oxytocin is classified as an essential medicine for reproductive health, underscoring its critical importance in maternal care globally. It is used in both resource-rich and resource-limited healthcare settings around the world.
What Should You Know Before Taking Oxytocin Pilum?
Quick Answer: Oxytocin Pilum must only be administered in a hospital setting under qualified medical supervision. There are several important contraindications, warnings, and precautions that healthcare providers must consider before administering this medication, including prior uterine surgery, certain cardiac conditions, and concurrent use of prostaglandins.
Contraindications
Oxytocin Pilum must not be used in the following situations:
- Hypersensitivity: Known allergy to oxytocin or any of the excipients (sodium acetate trihydrate, acetic acid, sodium chloride, sodium hydroxide, water for injections).
- Hypertonic uterine contractions: When the uterus is already contracting abnormally strongly, adding oxytocin could lead to uterine rupture or fetal distress.
- Cephalopelvic disproportion: When the baby's head is disproportionately large relative to the mother's pelvis, vaginal delivery may not be safely achievable.
- Abnormal fetal presentation: Malpresentation such as transverse lie or brow presentation that precludes safe vaginal delivery.
- Placenta previa or placental abruption: When the placenta is positioned in front of the baby or has prematurely separated from the uterine wall.
- Cord presentation or prolapse: When the umbilical cord is positioned ahead of the presenting fetal part.
- Overdistended uterus: Conditions such as grand multiparity (multiple previous pregnancies) or polyhydramnios (excessive amniotic fluid) that increase the risk of uterine rupture.
- Multiple pregnancy: Twin or higher-order pregnancies carry increased risk of complications with oxytocin augmentation.
- Uterine scarring: Previous uterine surgery, including cesarean section, myomectomy, or other procedures that have left scar tissue on the uterus.
- Recent prostaglandin use: Oxytocin Pilum must not be used within 6 hours of vaginal prostaglandin administration, as the combined effect of both drugs can cause dangerous uterine hyperstimulation.
Warnings and Precautions
Healthcare providers should exercise particular caution in the following circumstances:
- Cardiovascular disease: Patients with pre-existing cardiovascular conditions such as cardiomyopathy, valvular heart disease, or coronary artery disease (including angina) are at increased risk of blood pressure and heart rate changes. Rapid bolus injection can cause acute, short-lived hypotension followed by flushing and tachycardia, which may precipitate myocardial ischemia.
- Prolonged QT interval: Oxytocin has been associated with QT prolongation on ECG. Patients with known long QT syndrome, symptoms suggestive of QT prolongation, or those taking QT-prolonging medications require careful cardiac monitoring.
- Severe pre-eclampsia: Prolonged use of oxytocin is not recommended in patients with severe pre-eclamptic toxemia (characterized by hypertension, proteinuria, and edema occurring after the 24th week of gestation).
- Maternal age over 35: Older mothers may have reduced uterine compliance, increasing the risk of complications from oxytocin-augmented labor.
- Previous lower-segment cesarean section: While not an absolute contraindication in all cases, prior cesarean section increases the risk of uterine rupture with oxytocin use.
- Renal impairment: Patients with impaired kidney function may require dose reduction or longer dosing intervals, as oxytocin's antidiuretic effect can lead to water retention and hyponatremia.
- Latex allergy: The active substance in Oxytocin Pilum may cause serious allergic reactions (anaphylaxis) in patients with latex allergy. Inform your healthcare provider of any known latex sensitivity.
Oxytocin Pilum must only be administered in a hospital setting with continuous monitoring of uterine contractions and fetal heart rate. The infusion must be stopped immediately if uterine hyperactivity or fetal distress occurs. Qualified medical personnel and emergency resuscitation equipment must be immediately available.
Pregnancy and Breastfeeding
Oxytocin Pilum is specifically designed for use during pregnancy and the peripartum period. However, its use for induction of labor should only occur when strictly medically indicated, as determined by a qualified obstetrician or midwife. The decision to induce labor must carefully weigh the benefits of delivery against the risks of continued pregnancy and the potential complications of oxytocin use.
Regarding breastfeeding, oxytocin may be present in small amounts in breast milk, but this does not cause harmful effects on the newborn infant. In fact, endogenous oxytocin plays a physiological role in the milk let-down (ejection) reflex during breastfeeding. The European Medicines Agency (EMA) and other regulatory bodies consider oxytocin compatible with breastfeeding.
Sodium Content
Oxytocin Pilum contains less than 1 mmol (23 mg) of sodium per ampoule, making it essentially sodium-free. This is relevant for patients on sodium-restricted diets.
How Does Oxytocin Pilum Interact with Other Drugs?
Quick Answer: Oxytocin Pilum has clinically significant interactions with prostaglandins (which potentiate uterine contractions), inhalational anesthetics (which can reduce uterine response and cause arrhythmias), QT-prolonging drugs, and vasoconstrictor agents used with epidural anesthesia. Concurrent use of oxytocin nasal spray is contraindicated.
Drug interactions with oxytocin are particularly important in the obstetric setting, where multiple medications are often administered simultaneously during labor, delivery, and the immediate postpartum period. Healthcare providers must be aware of these interactions to ensure patient safety and optimize therapeutic outcomes.
Major Interactions
| Interacting Drug | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Prostaglandins (e.g., dinoprostone, misoprostol) | Synergistic uterotonic effect | Uterine hyperstimulation, possible rupture | Wait at least 6 hours after vaginal prostaglandins before starting oxytocin |
| Inhalational anesthetics (cyclopropane, sevoflurane, desflurane, halothane) | Reduced myometrial sensitivity; cardiovascular effects | Diminished uterine contractions, cardiac arrhythmias, enhanced hypotensive effect | Use lowest effective oxytocin dose; continuous cardiac monitoring |
| QT-prolonging drugs (certain antibiotics, antipsychotics, antiarrhythmics) | Additive QT prolongation | Increased risk of torsades de pointes and ventricular arrhythmia | ECG monitoring; avoid combination if possible |
| Oxytocin nasal spray | Additive oxytocin exposure | Excessive uterotonic stimulation | Do not use simultaneously |
Minor Interactions
| Interacting Drug | Clinical Effect | Recommendation |
|---|---|---|
| Epidural vasoconstrictor agents (e.g., epinephrine/adrenaline in local anesthetics) | Enhanced vasoconstrictor effect, potential hypertensive crisis | Monitor blood pressure closely when oxytocin is administered with epidural anesthesia |
| Large-volume IV fluids | Water intoxication due to oxytocin's antidiuretic effect; electrolyte dilution | Restrict oral and IV fluid intake; monitor serum sodium levels |
During oxytocin infusion, patients may be instructed to drink as little as possible. This is because oxytocin has an antidiuretic effect (similar to vasopressin/ADH), which can lead to water retention. When combined with excessive fluid intake or large-volume IV infusions, this may result in water intoxication, hyponatremia (dangerously low blood sodium), and potentially life-threatening cerebral edema.
What Is the Correct Dosage of Oxytocin Pilum?
Quick Answer: Oxytocin Pilum dosage varies by indication. For labor induction, it is given as a slow IV drip starting at 2–8 drops/min and gradually titrated upward. For cesarean section and postpartum hemorrhage, 1 ml (8.3 mcg) is administered as an IV infusion over 5 minutes. All dosing is performed by healthcare professionals in hospital settings with continuous monitoring.
Dosing of oxytocin requires careful individualization based on the clinical indication, the patient's response, and continuous monitoring of uterine activity and fetal well-being. The principle of using the lowest effective dose is paramount to minimize the risk of uterine hyperstimulation, fetal distress, and other complications.
Labor Induction and Augmentation
Intravenous Drip Infusion Protocol
Preparation: Dilute 0.2 ml of Oxytocin Pilum 8.3 mcg/ml (equivalent to 5 IU) in 100 ml of 5% glucose solution (for patients who should avoid sodium chloride) or 0.9% sodium chloride solution. Invert the bag or bottle several times to ensure thorough mixing.
Initial rate: 2–8 drops per minute (0.1–0.4 ml/min)
Titration: Increase infusion rate at intervals of at least 20 minutes, based on contraction frequency, duration, and fetal heart rate monitoring.
Maximum rate: 40 drops per minute (2 ml/min)
Discontinuation: Stop immediately if uterine hyperactivity or fetal distress occurs. If adequate contractions are not achieved after infusing a total of 8.3 mcg oxytocin, discontinue the attempt and consider repeating the following day.
Miscarriage and Abortion (Vacuum Aspiration)
Intravenous Infusion
Initial dose: 1.0 ml Oxytocin Pilum 8.3 mcg/ml diluted in 0.9% sodium chloride, administered as IV drip infusion or preferably via variable-rate infusion pump over 5 minutes.
During procedure: 6 ml Oxytocin Pilum in 500 ml of 5% glucose solution, infused intravenously during evacuation, beginning when cervix is dilated to Hegar No. 8. Maximum infusion rate during the procedure is approximately 15 ml/min. After the procedure, reduce to approximately 120 drops/min until the full volume is infused.
Postpartum Hemorrhage (Third Stage of Labor)
Intramuscular or Intravenous
Dose: 0.6–2.0 ml Oxytocin Pilum 8.3 mcg/ml (equivalent to 3–10 IU) given intramuscularly or as an intravenous infusion.
IV route: 1.0 ml diluted in 0.9% sodium chloride, administered as IV drip infusion or via infusion pump over 5 minutes.
Cesarean Section
Post-Delivery Infusion
Dose: 1.0 ml Oxytocin Pilum 8.3 mcg/ml diluted in 0.9% sodium chloride, administered as IV drip infusion or preferably via variable-rate infusion pump over 5 minutes, given after delivery of the baby.
Important: Rapid bolus injection must be avoided as it can cause acute hypotension, flushing, and reflex tachycardia, which may be particularly dangerous in patients with cardiovascular disease.
Special Populations
| Population | Recommendation |
|---|---|
| Hepatic impairment | Dose reduction or longer dosing intervals may be required |
| Renal impairment | Dose reduction or longer dosing intervals may be required; monitor for water retention |
| Elderly (≥65 years) | Not applicable; oxytocin is not intended for use in elderly patients |
| Pediatric | Not applicable; oxytocin is not intended for use in children |
Overdose
Oxytocin overdose can result in uterine hyperstimulation with prolonged tetanic contractions, which may lead to uterine rupture, fetal bradycardia, fetal asphyxia, meconium-stained amniotic fluid, placental abruption, and fetal death. Additionally, the antidiuretic effect of high-dose oxytocin can cause water intoxication with hyponatremia, hypoosmolality, and cerebral edema. Other signs include vascular spasm and hypertension. Treatment involves immediate discontinuation of the infusion and supportive care. If you suspect an overdose has occurred, inform healthcare personnel immediately.
What Are the Side Effects of Oxytocin Pilum?
Quick Answer: Like all medicines, Oxytocin Pilum can cause side effects, although not everyone experiences them. Common effects include headache, nausea, vomiting, and heart rate changes. Rare but serious effects include anaphylaxis, uterine rupture, water intoxication, and disseminated intravascular coagulation (DIC). Report any unusual symptoms to your healthcare provider immediately.
The side effects of oxytocin are well documented from decades of clinical use worldwide. Most side effects are dose-dependent and are more likely to occur at higher infusion rates or with prolonged administration. Healthcare professionals carefully monitor patients throughout oxytocin therapy to detect and manage adverse effects promptly.
Side Effect Frequency Overview
Common
May affect up to 1 in 10 patients
- Headache
- Decreased or increased heart rate (bradycardia/tachycardia)
- Nausea
- Vomiting
Uncommon
May affect up to 1 in 100 patients
- Cardiac arrhythmia (irregular heartbeat)
Rare
May affect up to 1 in 1,000 patients
- Skin rash
- Anaphylactic reactions (sudden rash, difficulty breathing, swelling, fainting)
- Laryngeal edema (swelling of the voice box)
- Anaphylactic shock (dangerously low blood pressure)
- Dyspnea (difficulty breathing)
Frequency Not Known
Reported from post-marketing surveillance
- Water intoxication (dilutional hyponatremia)
- Low blood sodium (hyponatremia)
- Chest pain due to myocardial ischemia
- QT prolongation on ECG
- Low blood pressure (hypotension)
- Acute pulmonary edema (fluid accumulation in the lungs)
- Disseminated intravascular coagulation (DIC)
- Uterine hypertonicity (excessively strong contractions)
- Uterine tetany (sustained contraction)
- Uterine rupture
- Flushing (sudden warmth sensation)
- Angioedema (swelling of face, tongue, or throat)
Effects on the Fetus and Newborn
Oxytocin administration can also affect the fetus and newborn, particularly when strong or prolonged uterine contractions occur. Reported fetal and neonatal adverse effects include:
- Fetal bradycardia: Slowing of the fetal heart rate, which may indicate fetal distress.
- Neonatal hyponatremia: Low blood sodium in the newborn, particularly when the mother has received large volumes of electrolyte-free fluids.
- Fetal asphyxia: Oxygen deprivation due to excessive or prolonged uterine contractions compromising placental blood flow.
- Neonatal jaundice: May occur more frequently in newborns exposed to oxytocin during delivery.
- Fetal death: In extremely rare cases, particularly associated with oxytocin overdose or uterine rupture.
Use of very high doses of oxytocin can cause excessively powerful uterine contractions, potentially leading to uterine tissue damage, uterine rupture, and serious fetal compromise. Rapid bolus administration (high initial dose) can cause acute, short-lived hypotension with subsequent flushing and tachycardia. In patients with pre-existing cardiovascular disease, this may lead to chest pain or myocardial ischemia.
Medicines used during labor, including oxytocin, may in rare cases increase the risk of blood clots forming in blood vessels after delivery (postpartum thromboembolism). This risk should be considered alongside other postpartum thrombotic risk factors such as immobility, cesarean section, and pre-eclampsia.
How Should You Store Oxytocin Pilum?
Quick Answer: Store Oxytocin Pilum in a refrigerator at 2–8 °C. Do not freeze. It can be stored at room temperature (up to 25 °C) for a maximum of 3 months. Once removed from refrigeration, do not return it to the fridge. After dilution, the infusion solution should be used within 24 hours.
Proper storage of oxytocin is critical to maintaining the drug's potency and safety. Oxytocin is a peptide hormone that is sensitive to temperature degradation. The WHO has specifically highlighted the importance of cold chain management for oxytocin, particularly in tropical and resource-limited settings where maintaining refrigeration can be challenging.
Storage Conditions
- Primary storage: Refrigerate at 2–8 °C (36–46 °F). Do not freeze.
- Room temperature storage: Within its shelf life, Oxytocin Pilum may be stored at up to 25 °C (77 °F) for a maximum of 3 months. If not used during this period, it must be discarded.
- Once removed from refrigeration: The product must not be returned to the refrigerator. The date of removal from refrigeration should be noted on the packaging.
- Before dilution: Each ampoule is for single use only and should be used immediately after opening. Discard any unused solution.
- After dilution: The prepared infusion solution should be used within 24 hours when stored at up to 25 °C. Discard any unused solution after this time.
- Expiry date: Do not use after the expiration date printed on the packaging (EXP). The expiry date refers to the last day of the stated month.
Keep out of sight and reach of children. Do not dispose of medicines via wastewater or household waste. Ask your pharmacist about proper disposal of medicines no longer in use, to help protect the environment.
What Does Oxytocin Pilum Contain?
Quick Answer: Each 1 ml ampoule contains 8.3 micrograms of oxytocin as the active ingredient. The excipients are sodium acetate trihydrate, acetic acid, sodium chloride, sodium hydroxide (for pH adjustment), and water for injections. It is supplied as a clear, colorless solution in transparent glass ampoules, in packs of 10.
Active Ingredient
The active substance is oxytocin. Each milliliter of solution contains 8.3 micrograms of oxytocin, equivalent to approximately 5 International Units (IU). Oxytocin is a cyclic nonapeptide hormone consisting of nine amino acids, with the sequence Cys–Tyr–Ile–Gln–Asn–Cys–Pro–Leu–Gly–NH2, with a disulfide bridge between the two cysteine residues.
Excipients (Inactive Ingredients)
| Excipient | Function |
|---|---|
| Sodium acetate trihydrate | Buffering agent |
| Acetic acid | pH adjustment |
| Sodium chloride | Tonicity agent (isotonicity) |
| Sodium hydroxide | pH adjustment |
| Water for injections | Solvent |
Pharmaceutical Form and Packaging
Oxytocin Pilum is presented as a clear, colorless solution in transparent 1 ml glass ampoules. Each pack contains 10 ampoules. The solution is sterile and intended for single use only. Unused solution must be discarded after opening. No antimicrobial preservative is present in the formulation.
Frequently Asked Questions About Oxytocin Pilum
Oxytocin Pilum is used in hospital settings to induce or augment labor contractions when medically necessary, manage incomplete or inevitable miscarriage, control and reduce postpartum hemorrhage (bleeding after delivery), and support uterine contraction during cesarean section. It contains the synthetic hormone oxytocin at a concentration of 8.3 micrograms per milliliter and is administered by healthcare professionals via intravenous infusion or intramuscular injection.
Synthetic oxytocin in Oxytocin Pilum is chemically identical to the natural oxytocin hormone produced by the body. However, when given as a medication, it allows healthcare providers to precisely control the dose and timing. Natural oxytocin is released in pulsatile fashion by the pituitary gland and plays roles in labor contractions, milk let-down during breastfeeding, and social bonding. The synthetic version targets the same oxytocin receptors in the uterus and produces the same uterotonic effect.
The most serious risks include uterine hyperstimulation (excessively strong or prolonged contractions), which can lead to uterine rupture and serious harm to both mother and baby. Water intoxication with severe hyponatremia and cerebral edema can occur, especially with prolonged high-dose infusions combined with large fluid volumes. Anaphylactic shock, though rare, is a potentially life-threatening allergic reaction. These risks are carefully managed through hospital-based administration with continuous fetal and uterine monitoring.
No. Oxytocin Pilum must only be administered in a hospital or clinical setting by qualified healthcare professionals. It requires continuous monitoring of uterine contractions and fetal heart rate during administration, as well as immediate access to emergency resuscitation equipment. Self-administration would pose extremely serious risks to both mother and baby, including uterine rupture, fetal distress, and death.
Yes. While small amounts of oxytocin may pass into breast milk, this has not been shown to cause harmful effects on the nursing infant. Oxytocin naturally plays an important role in the breastfeeding process by triggering the milk let-down reflex. Regulatory bodies including the European Medicines Agency consider therapeutic oxytocin use compatible with breastfeeding. Your healthcare provider can address any specific concerns.
Oxytocin is a peptide hormone that degrades when exposed to elevated temperatures for prolonged periods. The WHO has identified heat-related degradation of oxytocin as a significant concern, particularly in low-resource settings. Proper refrigerated storage (2–8 °C) preserves the drug's potency and ensures it works effectively when administered. While short-term room temperature storage (up to 25 °C for 3 months) is acceptable, exposure to higher temperatures or extended periods at room temperature can significantly reduce the drug's effectiveness.
References & Sources
This article is based on the following peer-reviewed sources and international medical guidelines:
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List (2023). Geneva: WHO.
- World Health Organization (WHO). WHO Recommendations: Uterotonics for the Prevention of Postpartum Haemorrhage (2018). Geneva: WHO.
- European Medicines Agency (EMA). Summary of Product Characteristics: Oxytocin-containing medicinal products. EMA/CHMP guidelines.
- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 107: Induction of Labor (reaffirmed 2023). Obstetrics & Gynecology.
- National Institute for Health and Care Excellence (NICE). Inducing Labour, NICE Guideline NG207 (2021, updated 2024). London: NICE.
- Gallos ID, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database of Systematic Reviews (2018), Issue 12. Art. No.: CD011689.
- Dyer RA, et al. Oxytocin in obstetrics: a review of cardiovascular effects. International Journal of Obstetric Anesthesia (2020); 43:47–56.
- Pilum Pharma A/S. Oxytocin Pilum 8.3 microgram/ml Solution for Injection/Infusion – Summary of Product Characteristics. Last updated January 2026.
- British National Formulary (BNF). Oxytocin Monograph. London: BMJ Group & Pharmaceutical Press. Accessed January 2026.
- Widmer M, et al. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. New England Journal of Medicine (2018); 379(8):743–752.
Medical Editorial Team
This article has been written and reviewed by our medical editorial team consisting of licensed physicians and clinical pharmacologists with specialist expertise in obstetrics, gynecology, and pharmacology.
Medical Review
Content reviewed by specialist physicians in obstetrics, gynecology and clinical pharmacology according to WHO, EMA, and ACOG guidelines.
Evidence Standard
All medical claims are supported by Level 1A evidence (systematic reviews of RCTs) following the GRADE framework. No commercial funding or pharmaceutical sponsorship.